IP Library Granted Patent US 10,980,461
Granted Patent B2
US 10,980,461 · App. 17/082,627 · Granted Apr 20, 2021

Advanced analyte sensor calibration and error detection

Inventors: Peter C. Simpson (Cardiff, CA); Ying Li (San Diego, CA); Apurv Ullas Kamath (San Diego, CA); Richard C. Yang (Carlsbad, CA)
Assignee: DexCom, Inc.
A61B5/1495A61B5/1451A61B5/1473A61B5/1486A61B5/14503A61B5/14517A61B5/14532A61B5/7257A61B5/7267G01D18/00G01N27/026G01N27/3274G01N33/49H05K999/00H05K999/99A61B5/14546A61B2560/0276
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,980,461
App. No.
17/082,627
Granted
Apr 20, 2021
Kind
B2
Abstract

Systems and methods for processing sensor data and self-calibration are provided. In some embodiments, systems and methods are provided which are capable of calibrating a continuous analyte sensor based on an initial sensitivity, and then continuously performing self-calibration without using, or with reduced use of, reference measurements. In certain embodiments, a sensitivity of the analyte sensor is determined by applying an estimative algorithm that is a function of certain parameters. Also described herein are systems and methods for determining a property of an analyte sensor using a stimulus signal. The sensor property can be used to compensate sensor data for sensitivity drift, or determine another property associated with the sensor, such as temperature, sensor membrane damage, moisture ingress in sensor electronics, and scaling factors.

Claims (50)

1. A system for monitoring a glucose concentration in a host, the system comprising:

a transcutaneous glucose sensor comprising:

an ex vivo portion configured to remain outside of a body of a host; and

an in vivo portion configured to be inserted into the body of the host, wherein the in vivo portion comprises:

a first electrode, wherein the first electrode is a working electrode;

a second electrode, wherein the second electrode is at least one of a reference electrode or a counter electrode; and

a membrane disposed over at least a portion of the first electrode; and

electronics configured to operably connect to the transcutaneous glucose sensor, wherein the electronics comprises a memory, wherein the memory stores information associated with a profile, wherein the profile is based at least in part on a priori sensitivity information related to expected sensitivity changes associated with a length of time the in vivo portion of the transcutaneous glucose sensor has been used or implanted.

2. The system of claim 1 , wherein the memory also stores information associated with a conversion function for calibrating data derived at least in part from the transcutaneous glucose sensor.

3. The system of claim 2 , wherein the data is derived at least in part from a signal generated by the transcutaneous glucose sensor.

4. The system of claim 2 , wherein the electronics further comprises a processor configured to calibrate data derived at least in part from the transcutaneous glucose sensor based at least in part on the conversion function and is further configured to apply the stored information associated with the profile during the calibrating.

5. The system of claim 2 , wherein the conversion function is based at least in part on a predictive relationship between in vitro sensitivity and in vivo sensitivity.

6. The system of claim 1 , wherein the memory also stores information associated with a calibration factor for calibrating data derived at least in part from the transcutaneous glucose sensor to compensate for a drift in sensor sensitivity.

7. The system of claim 1 , wherein the profile reflects a relationship between time and sensitivity, wherein the profile has a first slope associated with a first time range and a second slope associated with a second time range, wherein the first time range is different from the second time range, wherein the first slope is different from the second slope.

8. The system of claim 1 , wherein the electronics comprises sensor electronics.

9. The system of claim 1 , wherein the electronics comprises receiver electronics.

10. The system of claim 1 , wherein the electronics comprises sensor electronics and receiver electronics.

11. The system of claim 1 , wherein the system is configured for zero point calibration that enables conversion of raw sensor data into calibrated sensor data solely using information obtained prior to implantation of the transcutaneous glucose sensor.

12. The system of claim 1 , wherein the transcutaneous glucose sensor is configured to be calibrated without a need for a reference glucose value obtained after implantation in vivo.

13. A method of monitoring a glucose concentration in a host, the method comprising:

beginning a sensor session associated with use of a transcutaneous glucose sensor, wherein the transcutaneous glucose sensor comprises:

an ex vivo portion configured to remain outside of a body of a host; and

an in vivo portion, wherein the in vivo portion comprises:

a first electrode, wherein the first electrode is a working electrode;

a second electrode, wherein the second electrode is at least one of a reference electrode or a counter electrode; and

a membrane disposed over at least a portion of the first electrode; and

applying a processing algorithm to data derived at least in part from the transcutaneous glucose sensor, wherein the processing algorithm is based at least in part on a priori sensitivity information, wherein the a priori sensitivity information comprises an expected profile associated with sensitivity of the transcutaneous glucose sensor, wherein the profile is a function of time.

14. The system of claim 13 , wherein the data is derived at least in part from a signal generated by the transcutaneous glucose sensor.

15. The method of claim 13 , wherein the a priori sensitivity information is based at least in part on expected sensitivity changes associated with a length of time the transcutaneous glucose sensor has been used or implanted.

16. The method of claim 13 , wherein the applying comprises applying a conversion function for calibrating data.

17. The method of claim 13 , wherein the applying comprises applying a calibration factor for calibrating data.

18. The method of claim 17 , wherein the calibration factor is based at least in part on a predictive relationship between in vitro sensitivity and in vivo sensitivity.

19. The method of claim of claim 17 , wherein the data calibration is performed without a need for a reference glucose value obtained after implantation in vivo.

20. The method of claim 13 , wherein the profile reflects a relationship between time and sensitivity, wherein the profile has a first slope associated with a first time range and a second slope associated with a second time range, wherein the first time range is different from the second time range, wherein the first slope is different from the second slope.

21. The method of claim 13 , wherein the membrane is a membrane system comprising a plurality of different membrane layers.

22. The method of claim 13 , wherein the membrane is a single membrane layer.

23. The method of claim 13 , comprising receiving or retrieving the a priori sensitivity information from a memory prior to the applying.

24. A method for monitoring a glucose concentration over a course of a sensor session, the method comprising:

beginning a sensor session associated with use of a transcutaneous glucose sensor, wherein the transcutaneous glucose sensor comprises:

an ex vivo portion configured to remain outside of a body of a host; and

an in vivo portion configured to be inserted into the body of the host;

calibrating the transcutaneous glucose sensor by applying a priori information, wherein the a priori information comprises a profile, wherein the profile is associated with an expected pattern or amount of sensitivity change over a length of time the transcutaneous glucose sensor has been used or implanted;

generating a glucose concentration value based at least in part on the calibrating; and

displaying the glucose concentration value.

25. The method of claim 24 , wherein the generating comprises applying a conversion function to sensor data.

26. The system of claim 25 , wherein the sensor data is derived at least in part from a signal generated by the transcutaneous glucose sensor.

27. The method of claim 24 , wherein the generating comprises applying a calibration factor to sensor data.

28. The method of claim 27 , wherein the calibration factor is based at least in part on a predictive relationship between in vitro sensitivity and in vivo sensitivity.

29. The method of claim 24 , wherein the profile reflects a relationship between time and sensitivity, wherein the profile has a first slope associated with a first time range and a second slope associated with a second time range, wherein the first time range is different from the second time range, wherein the first slope is different from the second slope.

30. The method of claim 24 , wherein the calibrating is performed without a need for a reference glucose value obtained after implantation in vivo.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 5, 2021
From: SIMPSON, PETER C.
To: DEXCOM, INC.
Reel/Frame 055516/0507 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 23, 2020
From: LI, YING; KAMATH, APURV ULLAS; YANG, RICHARD C.
To: DEXCOM, INC.
Reel/Frame 054743/0759 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 19, 2020
From: BOHM, SEBASTIAN; RONG, DAITING; SIMPSON, PETER C.
To: DEXCOM, INC.
Reel/Frame 054487/0261 →
Continuity (14)
Continuation 16586610 · Sep 27, 2019
Continuation 16460943 · Jul 2, 2019
Continuation 16405887 · May 7, 2019
Continuation 15994905 · May 31, 2018
Continuation 14860392 · Sep 21, 2015
Continuation 13446977 · Apr 13, 2012
Continuation 13446848 · Apr 13, 2012
Continuation 17082627
Continuation In Part 16526910 · Jul 30, 2019
Continuation 16036808 · Jul 16, 2018
Continuation 14072659 · Nov 5, 2013
Continuation 12267525 · Nov 7, 2008
Provisional Application 61476145 · Apr 15, 2011
Related Publication 20210038129A1 · Feb 11, 2021
Cited By (51)
US 12,220,558 US 12,239,442 US 12,239,463 US 12,268,496 US 12,274,548 US 12,279,865 US 12,279,867 US 12,279,894 US 12,285,252 US 12,310,722 US 12,315,630 US 12,329,522 US 12,336,812 US 12,343,140 US 12,350,042 US 12,369,821 US 12,390,132 US 12,408,847 US 12,414,713 US 12,462,006 US 12,465,251 US 12,471,850 US 12,495,993 US 12,507,921 US 12,514,448 US 12,521,041 US 12,533,080 US 12,558,122 US 12,562,273 US 12,569,166 US 12,569,168 US 12,569,173 US 12,575,763 US 12,575,856 US 12,576,599 US 12,582,334 US 12,588,928 US 12,599,317 US 12,605,185 US 12,605,186 US 12,611,121 US 12,611,125 US 12,616,395 US 12,616,396 US 12,616,397 US 12,629,173 US 12,645,916 US 12,666,543 US 12,667,286 US 12,702,332 US 12,725,702